Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Monoamine_oxidase_inhibitors
|
| gptkbp:activities |
inhibits monoamine oxidase
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:1961
gptkb:FDA |
| gptkbp:brand |
Parnate
|
| gptkbp:class |
gptkb:drug
|
| gptkbp:clinical_trial |
Phase IV
|
| gptkbp:composed_of |
gptkb:chemical_compound
|
| gptkbp:contraindication |
gptkb:pheochromocytoma
liver disease concurrent use of certain medications |
| gptkbp:dissolved |
soluble in water
soluble in alcohol |
| gptkbp:dosage_form |
30 mg per day
60 mg per day |
| gptkbp:duration |
several weeks
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tranylcypromine
|
| gptkbp:ingredients |
C9 H10 N2
|
| gptkbp:interacts_with |
gptkb:beer
tyramine certain antidepressants certain pain medications |
| gptkbp:is_atype_of |
N06 A F01
|
| gptkbp:is_available_on |
generic medication
|
| gptkbp:is_used_for |
treatment of depression
|
| gptkbp:lifespan |
2 to 3 hours
|
| gptkbp:marketed_as |
various pharmaceutical companies
|
| gptkbp:metabolism |
liver
|
| gptkbp:notable_work |
impact on quality of life
long-term use effects comparative studies with SSR Is effects on neurotransmitters efficacy in treatment-resistant depression |
| gptkbp:research_areas |
neuropharmacology
psychopharmacology |
| gptkbp:safety_features |
Category C
|
| gptkbp:side_effect |
dizziness
insomnia dry mouth weight gain hypertensive crisis |
| gptkbp:social_structure |
phenethylamine derivative
|
| gptkbp:symptoms |
anxiety
fatigue irritability mood swings |
| gptkbp:type_of |
155-20-2
|